Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)

NCT01020747 | Completed Phase 1 Results

• 1 other identifier: VC-P001
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This phase I single center open labeled study is planned to assess the safety and tolerability of bevacizumab for treating patients with bilateral Recurrent Respiratory Papillomatosis (RRP). Approximately 20 patients will receive bevacizumab directly injected into the vocal folds. Patients who enroll in the protocol will be injected with bevacizumab in one vocal fold that represents the more diseased of the two folds. A sham injection with saline will be administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection. The investigator will also treat lesions by laser photoangiolysis of both vocal folds using the 532 nm potassium-titanyl-phosphate (KTP) laser.

Conditions

Recurrent Respiratory Papillomatosis

Outcome Measures

Primary Outcomes (1)

• The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient During and at the End of the 6-month Treatment Period.

  Prior to each treatment,the area of reappearance of disease was measured and the % change from baseline was calculated. The change was then added to the % change from the previous treatment to generate a cumulative total % change of reappearance of RRP from baseline. The additive nature of this parameter resulted in % greater than 100% if the area of vocal fold affected by the RRP increased over the baseline measurement.

  6 months

Interventions

Avastin® (bevacizumab) DRUG

Bevacizumab injections (\~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.

Also known as: Avastin®

Saline DRUG

A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female patients with dysphonia that have been diagnosed with Recurrent Respiratory Papillomatosis (RRP) of the vocal folds
• Age between 18 and 60 years old
• Female patients must be surgically sterilized, postmenopausal, or employ adequate contraception. Criteria for menopause are surgical menopause (hysterectomy, oophorectomy) or age \> 45 years with absence of menses for greater than 12 months and an elevated serum Hormone, follicle-stimulating (FSH) (\> 25 mIU/mL). Tubal ligation with menses within the past 12 months is not considered to be surgical sterilization.
• Have bilateral glottal papillomatosis (i.e., involving both the right and left vocal folds)
• Willing and able to comply with the investigational nature of the study and able to communicate well with investigators.
• Ability to comprehend and willingness to provide written informed consent in accordance with institutional and regulatory guidelines.

You may not qualify if:

• Have known sensitivity to bevacizumab
• Have been treated systemically with bevacizumab within 4 months (approximately 6 half-lives).
• Have hematocrits \< 30, elevated PT or PTT levels more than 1.2 X the upper limit of normal (ULN) or absolute platelet counts below the lower limit of normal (LLN).
• Have absolute neutrophil counts below 1500
• Have urine dipsticks positive for ≥3+ proteinuria will have spot urine collections and those patients with urine protein to urine creatinine ratios greater than 1.5.
• Have a history of congestive heart failure, angina that remains symptomatic despite medications, myocardial infarction or coronary artery disease-related procedure within the past 6 months (including angioplasty, stent placement, bypass graft surgery) or who have prosthetic heart valves.
• Have significant uncontrolled hypertension (systolic blood pressure above 160 and/or diastolic blood pressure above 100).
• Have had surgeries within 1 month of enrollment or who have un-healed surgical incisions at screening.
• Have a history of thromboembolic events, gastro-intestinal (GI) ulcer or bleeding, or with a history of wound dehiscence.
• Female patients that are pregnant, nursing or plan to nurse during the up to 18 months of treatment period.
• Patients with a history of bleeding disorders, documented platelet dysfunction, current use of anti-platelet drugs, or abnormal prothrombin time (PT) or activated partial thromboplastin timea (PTT) laboratory values as defined in number 3 above.

Sponsors & Collaborators

• Massachusetts General Hospital: lead

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Related Publications (23)

• Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science. 1983 Apr 29;220(4596):524-7. doi: 10.1126/science.6836297.

  PMID: 6836297 BACKGROUND

• Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg. 1999 Jul;125(7):743-8. doi: 10.1001/archotol.125.7.743.

  PMID: 10406310 BACKGROUND

• Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006 Mar;113(3):363-372.e5. doi: 10.1016/j.ophtha.2005.11.019. Epub 2006 Feb 3.

  PMID: 16458968 BACKGROUND

• Burns JA, Zeitels SM, Akst LM, Broadhurst MS, Hillman RE, Anderson R. 532 nm pulsed potassium-titanyl-phosphate laser treatment of laryngeal papillomatosis under general anesthesia. Laryngoscope. 2007 Aug;117(8):1500-4. doi: 10.1097/MLG.0b013e318064e869.

  PMID: 17585283 BACKGROUND

• Dedo HH, Yu KC. CO(2) laser treatment in 244 patients with respiratory papillomas. Laryngoscope. 2001 Sep;111(9):1639-44. doi: 10.1097/00005537-200109000-00028.

  PMID: 11568620 BACKGROUND

• Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91. doi: 10.1001/archotol.1995.01890120044008.

  PMID: 7488368 BACKGROUND

• Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18. doi: 10.1146/annurev.med.57.121304.131306.

  PMID: 16409133 BACKGROUND

• Franco RA Jr, Zeitels SM, Farinelli WA, Anderson RR. 585-nm pulsed dye laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol. 2002 Jun;111(6):486-92. doi: 10.1177/000348940211100603.

  PMID: 12090703 BACKGROUND

• Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006 Nov;90(11):1344-9. doi: 10.1136/bjo.2006.099598. Epub 2006 Jul 19.

  PMID: 16854824 BACKGROUND

• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691.

  PMID: 15175435 BACKGROUND

• Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand. 2007 Feb;85(1):119-20. doi: 10.1111/j.1600-0420.2006.00819.x. No abstract available.

  PMID: 17244226 BACKGROUND

• Meert AP, Feoli F, Martin B, Ninane V, Sculier JP. Angiogenesis in preinvasive, early invasive bronchial lesions and micropapillomatosis and correlation with EGFR expression. Histopathology. 2007 Feb;50(3):311-7. doi: 10.1111/j.1365-2559.2007.02610.x.

  PMID: 17257126 BACKGROUND

• Mounts P, Shah KV, Kashima H. Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5425-9. doi: 10.1073/pnas.79.17.5425.

  PMID: 6291043 BACKGROUND

• Parsons DS, Bothwell MR. Powered instrument papilloma excision: an alternative to laser therapy for recurrent respiratory papilloma. Laryngoscope. 2001 Aug;111(8):1494-6. doi: 10.1097/00005537-200108000-00030. No abstract available.

  PMID: 11568590 BACKGROUND

• Rahbar R, Vargas SO, Folkman J, McGill TJ, Healy GB, Tan X, Brown LF. Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2005 Apr;114(4):289-95. doi: 10.1177/000348940511400407.

  PMID: 15895784 BACKGROUND

• Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol. 2004 Oct;22(10):1198. doi: 10.1038/nbt1004-1198. No abstract available.

  PMID: 15470443 BACKGROUND

• Sachdev JC, Jahanzeb M. Evolution of bevacizumab-based therapy in the management of breast cancer. Clin Breast Cancer. 2008 Oct;8(5):402-10. doi: 10.3816/CBC.2008.n.048.

  PMID: 18952553 BACKGROUND

• Shehab N, Sweet BV, Hogikyan ND. Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy. 2005 Jul;25(7):977-89. doi: 10.1592/phco.2005.25.7.977.

  PMID: 16006276 BACKGROUND

• Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006 Apr;26(4):383-90. doi: 10.1097/01.iae.0000238561.99283.0e.

  PMID: 16603955 BACKGROUND

• Steinberg BM, DiLorenzo TP. A possible role for human papillomaviruses in head and neck cancer. Cancer Metastasis Rev. 1996 Mar;15(1):91-112. doi: 10.1007/BF00049489.

  PMID: 8842481 BACKGROUND

• Strong MS, Vaughan CW, Cooperband SR, Healy GB, Clemente MA. Recurrent respiratory papillomatosis: management with the CO2 laser. Ann Otol Rhinol Laryngol. 1976 Jul-Aug;85(4 Pt 1):508-16. doi: 10.1177/000348947608500412.

  PMID: 949157 BACKGROUND

• Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):81-7. doi: 10.1007/s00417-007-0660-z. Epub 2007 Aug 3.

  PMID: 17674014 BACKGROUND

• Zeitels, S.M. (2001). In Atlas of Phonomicrosurgery and Other Endolaryngeal Procedures for Benign and Malignant Disease (San Diego).

  BACKGROUND

Related Links

• Avastin package insert and information from the Genentech website.
• International RRP ISA site
• RRP Foundation website

MeSH Terms

Conditions

Recurrent respiratory papillomatosis

Interventions

Bevacizumab; Sodium Chloride

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Results Point of Contact

• Title: Monica Tettamanti
• Organization: Massachusetts General Hospital

mtettamanti@ccib.mgh.harvard.edu

617-643-5696

Study Officials

• Steven M Zeitels, MD

  Massachusetts General Hospital

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director: Center for Laryngeal Surgery and Voice Rehabilitation

Study Record Dates

• First Submitted: November 13, 2009
• First Posted: November 25, 2009
• Study Start: November 1, 2009
• Primary Completion: March 1, 2011
• Study Completion: March 1, 2011
• Last Updated: December 20, 2012
• Results First Posted: December 4, 2012

Record last verified: 2012-12

Locations

US (1)